Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Galli

Showing results (91-100 of 217) with videos related to

Pageof 22
Sort By:
Antiviral Therapy|June 9, 2006
Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapyGiovanni Sitia, Anna De Bona, Sabrina Bagaglio, et al.
European Journal of Epidemiology|June 23, 2012
Risk of type 2 diabetes among HIV-infected and healthy subjects in ItalyLaura Galli, Stefania Salpietro, Gabriele Pellicciotta, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2011
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLNicola Gianotti, Laura Galli, Sara Racca, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2012
Monotherapy with atazanavir as a simplification strategy: results from an observational studyFrancesca Cossarini, Stefania Salpietro, Laura Galli, et al.
The New Microbiologica|May 27, 2014
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirineSilvia Nozza, Laura Galli, Alba Bigoloni, et al.
The American Journal of Medicine|January 31, 2024
Clinical Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Immunocompromised Patients Treated During Omicron Sublineages Diffusion. Real-Life Experience from ASST LeccoFederico Conti, Silvia Pontiggia, Valentina Morena, et al.
AIDS (London, England)|December 15, 2010
Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individualsAnna Kajaste-Rudnitski, Laura Galli, Silvia Nozza, et al.
BMC Infectious Diseases|November 18, 2017
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patientsNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
The New Microbiologica|August 6, 2013
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimensAntonella Castagna, Laura Galli, Nicola Gianotti, et al.
BMC Infectious Diseases|January 8, 2017
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patientsVincenzo Spagnuolo, Laura Galli, Andrea Poli, et al.
Pageof 22

Showing results (91-100 of 217) with videos related to

Sort By:
Pageof 22
Antiviral Therapy|June 9, 2006
Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapyGiovanni Sitia, Anna De Bona, Sabrina Bagaglio, et al.
European Journal of Epidemiology|June 23, 2012
Risk of type 2 diabetes among HIV-infected and healthy subjects in ItalyLaura Galli, Stefania Salpietro, Gabriele Pellicciotta, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2011
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLNicola Gianotti, Laura Galli, Sara Racca, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2012
Monotherapy with atazanavir as a simplification strategy: results from an observational studyFrancesca Cossarini, Stefania Salpietro, Laura Galli, et al.
The New Microbiologica|May 27, 2014
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirineSilvia Nozza, Laura Galli, Alba Bigoloni, et al.
The American Journal of Medicine|January 31, 2024
Clinical Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Immunocompromised Patients Treated During Omicron Sublineages Diffusion. Real-Life Experience from ASST LeccoFederico Conti, Silvia Pontiggia, Valentina Morena, et al.
AIDS (London, England)|December 15, 2010
Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individualsAnna Kajaste-Rudnitski, Laura Galli, Silvia Nozza, et al.
BMC Infectious Diseases|November 18, 2017
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patientsNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
The New Microbiologica|August 6, 2013
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimensAntonella Castagna, Laura Galli, Nicola Gianotti, et al.
BMC Infectious Diseases|January 8, 2017
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patientsVincenzo Spagnuolo, Laura Galli, Andrea Poli, et al.
Pageof 22